JP2024515826A5 - - Google Patents
Info
- Publication number
- JP2024515826A5 JP2024515826A5 JP2023566511A JP2023566511A JP2024515826A5 JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5 JP 2023566511 A JP2023566511 A JP 2023566511A JP 2023566511 A JP2023566511 A JP 2023566511A JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5
- Authority
- JP
- Japan
- Prior art keywords
- biodegradable
- implant according
- ophthalmic implant
- compound
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182559P | 2021-04-30 | 2021-04-30 | |
| US63/182,559 | 2021-04-30 | ||
| US202163287737P | 2021-12-09 | 2021-12-09 | |
| US63/287,737 | 2021-12-09 | ||
| PCT/US2022/027048 WO2022232588A1 (en) | 2021-04-30 | 2022-04-29 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515826A JP2024515826A (ja) | 2024-04-10 |
| JP2024515826A5 true JP2024515826A5 (cg-RX-API-DMAC7.html) | 2025-05-20 |
Family
ID=83848732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566511A Pending JP2024515826A (ja) | 2021-04-30 | 2022-04-29 | 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11786510B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329753A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024515826A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240004643A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022264036A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022705A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307997A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012723A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232588A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| AU2024405327A1 (en) * | 2023-12-20 | 2026-07-02 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US6573285B2 (en) * | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| CZ20032350A3 (en) | 2001-02-02 | 2004-03-17 | Merck Patent Gmbh | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| US20030176356A1 (en) | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| AR080888A1 (es) | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| EP4046628A1 (en) | 2013-10-31 | 2022-08-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| ES2813383T3 (es) | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| JP2018522942A (ja) * | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| CN115337254A (zh) | 2015-07-23 | 2022-11-15 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US10905770B2 (en) * | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| CA3132635A1 (en) | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
| KR102191180B1 (ko) * | 2019-05-31 | 2020-12-15 | 삼진제약주식회사 | 안질환 치료용 조성물 |
| JP7664239B2 (ja) * | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
-
2022
- 2022-04-29 BR BR112023022705A patent/BR112023022705A2/pt unknown
- 2022-04-29 IL IL307997A patent/IL307997A/en unknown
- 2022-04-29 WO PCT/US2022/027048 patent/WO2022232588A1/en not_active Ceased
- 2022-04-29 EP EP22796857.5A patent/EP4329753A4/en active Pending
- 2022-04-29 KR KR1020237040742A patent/KR20240004643A/ko active Pending
- 2022-04-29 MX MX2023012723A patent/MX2023012723A/es unknown
- 2022-04-29 AU AU2022264036A patent/AU2022264036A1/en active Pending
- 2022-04-29 JP JP2023566511A patent/JP2024515826A/ja active Pending
- 2022-04-29 CA CA3218251A patent/CA3218251A1/en active Pending
- 2022-11-30 US US18/060,503 patent/US11786510B2/en active Active
-
2023
- 2023-09-07 US US18/463,102 patent/US12622894B2/en active Active
-
2025
- 2025-06-09 US US19/232,649 patent/US20260130890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230172842A1 (en) | Sustained drug delivery implant | |
| AU2015257651B2 (en) | Compounds for treating ophthalmic diseases and disorders | |
| RU2532333C2 (ru) | Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний | |
| CN103002884B (zh) | 用前房内比马前列素植入物的眼内压降低 | |
| CN107184544A (zh) | 前房内持续释放治疗药植入物 | |
| JP2022506111A5 (cg-RX-API-DMAC7.html) | ||
| JP2014014694A (ja) | 血管拡張薬を含有する持続放出性眼内インプラント | |
| JP7330510B2 (ja) | 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物 | |
| WO2014066658A1 (en) | Ketorolac-containing sustained release drug delivery systems | |
| TW202345803A (zh) | 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 | |
| CN114746079A (zh) | 用于预防或治疗眼部疾病的滴眼剂组合物 | |
| JPWO2019151470A1 (ja) | 眼内血管新生及び/又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 | |
| JP6407145B2 (ja) | 網脈絡膜障害の抑制剤 | |
| WO2020242264A1 (en) | A composition for treating eye diseases | |
| EP3328411A1 (en) | Sustained-release drug formulations for glaucoma | |
| HK40118703A (en) | Method of treating wet age-related macular degeneration | |
| CN118891040A (zh) | 治疗湿性年龄相关性黄斑变性的方法 | |
| HK40092417A (en) | Compounds for treating ophthalmic diseases and disorders | |
| JP2009544740A5 (cg-RX-API-DMAC7.html) | ||
| HK1183436B (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| HK1183436A (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| WO2004037246A1 (ja) | 神経線維再生促進剤 |